Sanofi to invest 1.3 bln euros in new insulin plant in Frankfurt
LONDON/WASHINGTON, July 30 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S. states told Reuters.
LONDON/WASHINGTON, July 12 (Reuters) - Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.
July 10 (Reuters) - The U.S. Federal Trade Commission is planning to sue UnitedHealth (UNH.N), opens new tab, Cigna (CI.N), opens new tab and CVS Health (CVS.N), opens new tab over their tactics as middlemen in negotiating prices for drugs including insulin, a person familiar with the matter said on Wednesday.
July 10 (Reuters) - The U.S. Food and Drug Administration has declined to approve Novo Nordisk's (NOVOb.CO), opens new tab weekly insulin in patients with diabetes, the Danish drugmaker said on Wednesday.
JAKARTA, July 10 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab has signed a deal with Indonesia's state-owned pharmaceutical company Bio Farma to produce insulin to combat diabetes in the Southeast Asian country, a Bio Farma senior official said on Wednesday.
VIENNA, July 9 (Reuters) - Austrian prosecutors said they will bring criminal charges against two men accused of selling fake versions of Novo Nordisk's (NOVOb.CO), opens new tab diabetes drug Ozempic, resulting in bodily harm in three women.
A new weekly insulin dosage by Novo Nordisk, Insulin Icodec, is on the brink of approval in India, offering potential relief for those who require daily insulin injections. The Subject Expert Committee has recommended permitting the import and sale of this innovative product, expected to revolutionise the insulin market. While further studies are required, doctors anticipate improved patient compliance with this new treatment option.
– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte’s stem cell-derived islets observed to restore normal blood glucose...